AI in Healthcare

The latest on artificial intelligence transforming medicine

News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.

Filtered by: small moleculesClear filter
opiniondrugdiscoverytrends.com

Small Meets Large: Pharma Rethinks the Molecule Divide in a More AI-Native R&D Model

A new industry analysis argues that the historic split between small molecules and large molecules is becoming less useful in pharmaceutical R&D. As AI-driven design and platform biology mature, developers are increasingly organizing around disease mechanisms, developability, and modality fit rather than legacy chemistry silos.

pharma R&Dsmall moleculesbiologicsAI drug discovery
industry

Takeda’s $1.7 Billion Iambic Bet Shows Big Pharma Still Pays for AI-Validated Small-Molecule Platforms

Takeda and Iambic Therapeutics have announced a deal worth up to $1.7 billion to advance small-molecule programs, adding another major validation point for AI-enabled drug discovery. The agreement suggests large pharma remains willing to spend heavily when platform claims are tied to tangible pipeline output rather than abstract model performance.

MSN
TakedaIambic TherapeuticsAI drug discovery

How this works

Discover

An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.

Structure

The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.

Publish

Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.